Abstract
Background Acute myocardial infarction (AMI) remains a major cause of death, with limited understanding of its early risk stratification. While late-stage AMI has recognized associations with gut microbiome disturbances, the connection to eAMI is less explored.
Methods Using metabolomics and metagenomics, we analyzed 56 samples, comprising 30 eAMI patients (within 12 hours of onset) and 26 age- and gender-matched healthy controls, to discern the influence of gut microbes and their metabolites.
Results We found the eAMI plasma is dominated by increased long-chain fatty acids (LCFAs), 14 of which provide differentiating power of eAMI patients from HCs. Multiomics analysis reveals up to 70% of the variance in LCFAs of eAMI patients can be explained by altered gut microbiome. Higher-resolution profiling of gut bacterial species demonstrated that bacterial structural variations are mechanistically linked to LCFAs dysregulation. By in silico molecular docking and in vitro thrombogenic assay in isolated human platelets, we highlighted that eAMI-associated LCFAs contribute to platelet aggregation, a driving factor for AMI initiation.
Conclusions LCFAs hold significant potential as early biomarkers of AMI and gut microbiome contributes to altered LCFAs in eAMI. Further studies are imperative to expand upon these observations to better leverage LCFAs as a potential biomarker for eAMI and as a therapeutic target for inhibition of platelet aggregation in eAMI.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported by the Key research and development project of Zhejiang Province, China (no. 2021C03096), Major Project of Science and Technology Innovation 2025 in Ningbo, China (no. 2021Z134) and Ningbo Clinical Research Center for Cardiovascular Disease, Ningbo, China (no. 2022L001).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by the Ethics Committee of The First Affiliated Hospital of Ningbo University (No. 2021-R018-YJ01). The study was performed in accordance with the principles of the Declaration of Helsinki. All participants provided written, informed consent for participation in the study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
The metadata are available under restricted access due to participant consent and privacy regulations of this cohort, access can be obtained by request to the corresponding author. Access to the metagenomics and metabolomics data may be granted for statistical and scientific research with approval from the corresponding author (Hanbin Cui: hbcui_nbdyyy{at}outlook.com).
